CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 705 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 705 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total value of $13,951.95. Following the sale, the chief technology officer owned 166,912 shares of the company’s stock, valued at $3,303,188.48. This trade represents a 0.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Raymond Woo also recently made the following trade(s):

• On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $21.18, for a total transaction of $235,352.16.
• On Monday, December 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $12.28, for a total transaction of $136,455.36.

CeriBell Stock Performance

Shares of CBLL stock traded down $0.09 during mid-day trading on Thursday, hitting $18.86. The stock had a trading volume of 143,858 shares, compared to its average volume of 345,803. The firm has a market cap of $699.71 million, a PE ratio of -12.83 and a beta of 1.03. The company’s 50-day simple moving average is $21.20 and its 200-day simple moving average is $16.19. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $25.37.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 30.99%. Sell-side analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CeriBell during the 3rd quarter valued at approximately $33,000. CWM LLC grew its position in shares of CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after buying an additional 1,256 shares in the last quarter.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on EPS and revenue — CeriBell reported Q4 EPS of ($0.36) vs. a consensus of ($0.43) and revenue of $24.78M vs. $23.95M expected, a beat that supports the recent uptick in the share price. MarketBeat: Q4 Results & Conference Call
• Positive Sentiment: FY‑2026 revenue guidance provided — Management gave revenue guidance of roughly $111M–$115M for FY‑2026, which is close to consensus (~$112.7M), offering a clearer growth target for the year. Business Insider: Full Year Results & Guidance
• Positive Sentiment: Earnings call highlighted revenue surge and market expansion — Management commentary and the call transcript emphasized accelerating revenue and expansion into new markets, supporting upside potential if execution continues. Yahoo Finance: Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest data appears unreliable this cycle — the published short‑interest entry shows zero shares / NaN change, which is likely a reporting artifact and provides no actionable signal today.
• Negative Sentiment: Multiple insider sales disclosed — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold small amounts of stock at roughly $19.79–$19.98, reducing their positions by fractions of a percent; while sizes are modest relative to total holdings, clustered insider selling can create short‑term investor concern. InsiderTrades: Xingjuan Chao Sale SEC Filing: CEO Ownership

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Canaccord Genuity Group boosted their target price on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.